Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is -23.03%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.16%.
RETURN ON ASSETS (ROA)
-23.03%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+28.57%
vs the sector median at left
SpyGlass Pharma, Inc. Common Stock
Market Cap
$841.35M
Return on Assets (ROA)
-23.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$841.30M
Return on Assets (ROA)
-18.34%
TTM Avg
-25.78%
3Y Avg
-11.37%
5Y Avg
4.46%
Market Cap
$838.83M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$843.28M
Return on Assets (ROA)
-17.48%
TTM Avg
-47.13%
3Y Avg
-32.40%
5Y Avg
-21.92%
Market Cap
$837.55M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$834.66M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$852.35M
Return on Assets (ROA)
-135.59%
TTM Avg
-77.84%
3Y Avg
-48.75%
5Y Avg
-48.75%
Market Cap
$857.05M
Return on Assets (ROA)
-5.88%
TTM Avg
-10.67%
3Y Avg
-19.76%
5Y Avg
-21.39%
Market Cap
$863.03M
Return on Assets (ROA)
61.78%
TTM Avg
41.06%
3Y Avg
4.27%
5Y Avg
-3.43%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. Common Stock (SGP) | $841.35M | -23.03% | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $841.30M | -18.34% | -25.78% | -11.37% | 4.46% |
| Beta Bionics, Inc. (BBNX)vs › | $838.83M | -24.96% | -29.43% | -70.30% | -70.30% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $843.28M | -17.48% | -47.13% | -32.40% | -21.92% |
| Alumis Inc. (ALMS)vs › | $837.55M | -78.30% | -72.68% | -105.45% | -105.45% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $834.66M | -23.15% | -12.59% | -25.36% | -32.38% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -135.59% | -77.84% | -48.75% | -48.75% |
| SI-BONE, Inc. (SIBN)vs › | $857.05M | -5.88% | -10.67% | -19.76% | -21.39% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $863.03M | 61.78% | 41.06% | 4.27% | -3.43% |
| Ardelyx, Inc. (ARDX)vs › | $813.96M | -9.67% | -10.63% | -19.71% | -38.52% |
ROA
-23.0%
ROE
-24.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -34.41% |
